Adjuvant CDK4/6 inhibitors combined with endocrine ...

July 6, 2021

Adjuvant CDK4/6 inhibitors with ET showed potential in prolonging IDFS for HR+/HER2- EBC, especially in N2/N3 patients, but with higher grade 3/4 AEs and treatment discontinuation risks. Evidence remains inconclusive, necessitating further trials for validation.

Related Clinical Trials

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

PALbociclib CoLlaborative Adjuvant Study

Reference News

pmc.ncbi.nlm.nih.gov

Adjuvant CDK4/6 inhibitors combined with endocrine ...